Ritlecitinib bulk supplier for pharma manufacturers

Ritlecitinib 50 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 50 mg

Reference Brands: Litfulo (USA/EU)

Ritlecitinib is used to treat severe alopecia areata. It works as a selective JAK3/TEC family kinase inhibitor that helps reduce immune-mediated hair follicle damage, supporting hair regrowth in patients with autoimmune-related hair loss. It is taken orally once daily.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ritlecitinib? List it or send an offer →

Product Description:

Ritlecitinib inhibits two targets: Janus kinase 3 and the TEC family of kinases. JAK3 blockade interrupts signalling from the common gamma chain cytokines that lymphocytes depend on, and TEC inhibition reduces the cytotoxic activity of CD8 T cells and natural killer cells. In alopecia areata those cells attack the hair follicle, stripping it of the immune privilege that normally protects it.

It is used for severe alopecia areata in adults and adolescents aged twelve and over, taken once daily. In trials a substantial proportion achieved significant scalp hair regrowth by six to nine months, with responses continuing to improve over longer follow-up. Because JAK3 signalling is confined largely to immune cells, the haematological effects of broader JAK inhibition are less prominent, but the oral JAK class warnings still apply: serious infection, tuberculosis, herpes zoster, thrombosis, cardiovascular events and malignancy, with screening before and monitoring during treatment.

Sourcing notes. Originator product, on patent, no generic. Registered in the US, EU and other markets. Supply is through authorised distribution. Alopecia areata is often treated as cosmetic by payers, so reimbursement status — not clinical demand — is what determines volume in each market.

How Ritlecitinib is supplied today, and licensing ahead of patent expiry

Ritlecitinib is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Ritlecitinib, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Ritlecitinib supply →

Back to Listing

Frequently Asked Questions

Ritlecitinib is used to treat severe alopecia areata, an autoimmune condition that causes hair loss.

Ritlecitinib is a small molecule that selectively inhibits Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases.

The trade name is Litfulo.

Litfulo is made by Pfizer.

The generic name is ritlecitinib.

The brand name is Litfulo.

It is manufactured in the United States by Pfizer.

Litfulo (Ritlecitinib) is developed and sold by Pfizer. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.